Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin

Published:2018-10-23 Issue:1 Volume:37 Page:35-38
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Chihara Dai¹^ORCID,Wong Shannon²,Feldman Tatyana³,Fanale Michelle A.¹,Sanchez Larysa³,Connors Joseph M.²,Savage Kerry J.²,Oki Yasuhiro¹

Affiliation:

1. Department of Lymphoma/MyelomaThe University of Texas MD Anderson Cancer Center Houston TX USA

2. Department of Lymphoid Cancer Research, BC Cancer AgencyBC Cancer Centre for Lymphoid Cancer Vancouver BC Canada

3. Department of HematologyJohn Theurer Cancer Center at Hackensack University Medical Center Hackensack NJ USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2560

Reference11 articles.

1. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

3. The biology and management of systemic anaplastic large cell lymphoma

4. The survival outcome of the patients with relapsed/refractory anaplastic large‐cell lymphoma;Chihara D;Blood,2015

5. Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin;New England Journal of Medicine;2024-06-13

2. Allogeneic haematopoietic cell transplant in patients with relapsed/refractory anaplastic large cell lymphoma;British Journal of Haematology;2022-09-19

3. Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL;Cancers;2021-11-29

4. Traditional and emerging therapies for anaplastic large cell lymphoma (Review);International Journal of Oncology;2021-06-14

5. Targeted based therapy in nodal T-cell lymphomas;Leukemia;2021-03-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3